Learning Objectives: -Assess the expanding treatment landscape for patients with NHL, including new and emerging non-CART options such as bispecific antibodies, and its impact on individualized treatment selection and treatment sequencing. -Analyze available CAR T-cell therapies for patients with relapsed/refractory NHL based on the latest safety and efficacy trial data and currently approved indications. -Conduct comprehensive evaluation to determine eligibility and potential benefits of CAR T-cell therapy based on recent clinical trial data, guideline recommendations, as well as patient-, disease-, and treatment-specific factors. -Identify suitable candidates that might benefit from CAR T-cell therapy in an outpatient setting versus an inpatient setting to support patient preference and satisfaction. -Apply a multidisciplinary approach to coordinate care between referring physician, establishing outpatient CART centers, and cross-collaboration with clinical teams to ensure individualized and optimal patient management.
- Provider:Medical Learning Institute, Inc.
- Activity Link: https://learn.mlieducation.org/courses
- Start Date: 2024-06-15 05:00:00
- End Date: 2024-06-15 05:00:00
- Credit Details: IPCE Credits: 1.0 hours
AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours - MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Bristol Myers Squibb - Amount: 44475.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Hematology, Internal Medicine, Medical Oncology